Skip to main content

Table 4 Hypoxia mimicked with CoCl2 provides stronger resistance to carboplatin

From: Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer

A.

Treatments – cell death analysis (48 h)

Tukey test sig.

ES2-AN Ctr vs Carbopltin

0.008

ES2-ANC Ctr vs Carbopltin

0.000

ES2-AH Ctr vs Carbopltin

0.019

ES2-AHC Ctr vs Carbopltin

0.0000

ES2-NN Ctr vs Carbopltin

0.008

ES2-NNC Ctr vs Carbopltin

0.002

ES2-NH Ctr vs Carbopltin

0.069

ES2-NHC Ctr vs Carbopltin

0.006

ES2-HN Ctr vs Carbopltin

0.412

ES2-HNC Ctr vs Carbopltin

0.175

ES2-HH Ctr vs Carbopltin

0.016

ES2-HHC Ctr vs Carbopltin

0.706

B.

Treatments – cell death analysis (48 h)

Tukey test sig.

ES2-HN vs ES2-AN

0.001

ES2-HN vs ES2-NN

0.000

ES2-HNC vs ES2-ANC

0.000

ES2-HNC vs ES2-NNC

0.001

ES2-HHC vs ES2-AHC

0.000

ES2-HHC vs ES2-NHC

0.001

C.

Treatments – cell death analysis (48 h)

Tukey test sig.

OVCAR3-AN Ctr vs Carbopltin

0.000

OVCAR3-ANC Ctr vs Carbopltin

0.000

OVCAR3-AH Ctr vs Carbopltin

0.000

OVCAR3-AHC Ctr vs Carbopltin

0.000

OVCAR3-NN Ctr vs Carbopltin

0.000

OVCAR3-NNC Ctr vs Carbopltin

0.000

OVCAR3-NH Ctr vs Carbopltin

0.026

OVCAR3-NHC Ctr vs Carbopltin

0.000

OVCAR3-HN Ctr vs Carbopltin

0.000

OVCAR3-HNC Ctr vs Carbopltin

0.000

OVCAR3-HH Ctr vs Carbopltin

0.000

OVCAR3-HHC Ctr vs Carbopltin

0.001

D.

Treatments – cell death analysis (48 h)

Tukey test sig.

OVCAR3-HN vs OVCAR3-AN

0.002

OVCAR3-HN vs OVCAR3-NN

0.001

OVCAR3-HHC vs OVCAR3-NHC

0.013